The
Automation Partnership Announces David Phillips as New Commercial Director
(Cambridge
UK, January 09, 2003) The
Automation Partnership (TAP), a world leader in life science automation
systems, announced today that David
Phillips has joined the board of the Company as Commercial Director.
In this critical leadership role, Mr. Phillips will have executive
responsibility for the global sales, marketing and business development
activities of TAP’s drug discovery, genomics and cell culture divisions.
TAP
Chief Executive Richard Archer, commented, “I am delighted that David
has joined TAP. He has exceptional experience both in our current areas of
activity and in the new areas of business we are pursuing. David’s
arrival continues the process of broadening and developing the executive
management team at TAP and he is a key part of our future plans for the
business”
“I am thrilled to be joining The Automation Partnership team,” stated
Mr. Phillips. “I look
forward to building upon the world-class brand name and market reputation
TAP has already established and developing new opportunities that will
promote continued growth. I
am excited to
utilise
my business development experience, as well as my background in both
‘big pharmaceutical’ and start-up environments, to help shape TAP’s
long term strategy and forge significant partnerships, alliances and joint
ventures,” he added.
Mr.
Phillips brings to TAP a wealth of experience in both the pharmaceutical
and biotechnology industries. Most
recently, he served as Chief Commercial Officer with Argenta Discovery,
where he delivered commercial leadership worldwide and established key
strategic partnerships with companies such as GlaxoSmithKline. Previously, Mr. Phillips was Chief Executive Officer of Oxxon
Pharmaccines, where he was instrumental in establishing that early stage
company as a competitive force in the therapeutic vaccine sector.
Responsible for overall management of the company, Mr. Phillips
successfully created and achieved the business plan, forged relationships
with key influential audiences and secured second round funding.
Mr.
Phillips was instrumental in the establishment of Cambridge Discovery
Chemistry. On its acquisition by Oxford Molecular, he held several
positions including Vice President, Business Development and Vice
President, Group Sales & Marketing.
He was employed by GlaxoWellcome plc for fourteen years, where he
held key marketing and sales roles including Head of Cardiovascular,
Diabetes and New Therapy Areas Group.
Copy
Ends
For more
information, please contact
About
The Automation Partnership
The
Automation Partnership is a world leader in the design and development of
advanced industrial automation solutions for the life science industry.
With
a successful track record in automating and integrating processes for cell
culture, compound and sample management, liquid handling and ultra high
throughput screening, the Company continues to develop and implement
market driven automation solutions to meet the discovery, development and
commercial challenges of the 21st Century.
The
company’s systems are installed worldwide at leading life science
companies such as Amgen, AstraZeneca, Bristol-Myers Squibb, Centre
National de Génotypage, GlaxoSmithKline, Max Planck Institute for
Molecular Genetics, Merck and Procter & Gamble.
Originated
in 1988, The Automation Partnership is a private company with over 180
staff in Europe and the United States.
The company’s headquarters and production and development
facilities are located in Cambridge, England, with a US sales and support
office in Wilmington, Delaware.
Additional information
about The Automation Partnership can be found at www.automationpartnership.com
.
